Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase

NCT01872442 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Chronic Phase of Chronic Myeloid Leukemia

Interventions

DRUG: Dasatinib
DRUG: Peg-Interferon alpha2b

Sponsor

Poitiers University Hospital